Outcomes in stage i testicular seminoma: A population-based study of 9193 patients

Cancer

Volumn 119, Issue 15, 2013, Pages 2771-2777

  Beard, Clair J ^a   Travis, Lois B ^b   Chen, Ming Hui ^c   Arvold, Nils D ^a   Nguyen, Paul L ^a   Martin, Neil E ^a   Kuban, Deborah A ^d   Ng, Andrea K ^a   Hoffman, Karen E ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

all cause mortality; cardiovascular disease; radiotherapy; second malignant neoplasm; seminoma; suicide; survivor; testicular cancer

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; SEMINOMA; STAGE 1 TESTICULAR SEMINOMA; STANDARDIZED MORTALITY RATIO; SUICIDE; SURVIVAL RATE;

ALL-CAUSE MORTALITY; CARDIOVASCULAR DISEASE; RADIOTHERAPY; SECOND MALIGNANT NEOPLASM; SEMINOMA; SUICIDE; SURVIVOR; TESTICULAR CANCER;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEER PROGRAM; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84880573642     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28086     Document Type: Article

References (38)

1. Li C, Ekwueme DU, Rim SH, Tangka FK,. Years of potential life lost and productivity losses from male urogenital cancer deaths-United States, 2004. Urology. 2010; 76: 528-535.
2. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV,. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol. 2008; 26: 3937-3942.
3. Yu HY, Madison RA, Setodji CM, Saigal CS,. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol. 2009; 27: 4327-4332.
4. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005; 97: 1354-1365.
5. Zagars GK, Ballo MT, Lee AK, Strom SS,. Mortality after cure of testicular seminoma. J Clin Oncol. 2004; 22: 640-647.
6. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007; 25: 4370-4378.
7. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003; 21: 1513-1523.
8. Zippin C, Lum D, Hankey BF,. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76: 2343-2350.
9. Fossa SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011; 29: 963-970.
10. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993; 88: 400-409.
11. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
12. Ulm K,. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990; 131: 373-375.
13. Taeger D, Sun Y, Keil U, Straif K,. A stand-alone windows applications for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies. Epidemiology. 2000; 11: 607-608.
14. Bokemeyer C, Schmoll HJ,. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol. 1993; 11: 1703-1709.
15. Cox DR,. Regression models and life-tables. J R Stat Soc Series B Methodol. 1972; 34: 187-220.
16. Cox DR,. Partial likelihood. Biometrika. 1975; 62: 269-276.
17. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
18. Travis LB, Boice JD, Jr,., Allan JM, et al. Second Primary Cancers and Cardiovascular Disease After Radiation Therapy: National Council on Radiation Protection and Measurements (NCRP), Report No. 170, 2011.
19. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010; 102: 1114-1130.
20. Wethal T, Kjekshus J, Roislien J, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv. 2007; 1: 8-16.
21. Misono S, Weiss NS, Fann JR, Redman M, Yueh B,. Incidence of suicide in persons with cancer. J Clin Oncol. 2008; 26: 4731-4738.
22. Trask PC, Paterson AG, Fardig J, Smith DC,. Course of distress and quality of life in testicular cancer patients before, during, and after chemotherapy: results of a pilot study. Psychooncology. 2003; 12: 814-820.
23. Dahl AA, Haaland CF, Mykletun A, et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol. 2005; 23: 2389-2395.
24. Hamza CA, Stewart SL, Willoughby T,. Examining the link between nonsuicidal self-injury and suicidal behavior: a review of the literature and an integrated model. Clin Psychol Rev. 2012; 32: 482-495.
25. Kendal WS,. Suicide and cancer: a gender-comparative study. Ann Oncol. 2007; 18: 381-387.
26. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000; 92: 1165-1171.
27. Fossa SD, Langmark F, Aass N, Andersen A, Lothe R, Borresen AL,. Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer. 1990; 61: 639-643.
28. Zwahlen DR, Ruben JD, Jones P, Gagliardi F, Millar JL, Schneider U,. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 539-545.
29. Schairer C, Hisada M, Chen BE, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst. 2007; 99: 1248-1256.
30. Curtis RE, Freedman DM, Ron E, et al. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publ No. 05-5302. Bethesda, MD: National Cancer Institute; 2006.
31. Groll RJ, Warde P, Jewett MA,. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007; 64: 182-197.
32. McFarland W, Chen S, Hsu L, Schwarcz S, Katz M,. Low socioeconomic status is associated with a higher rate of death in the era of highly active antiretroviral therapy, San Francisco. J Acquir Immune Defic Syndr. 2003; 33: 96-103.
33. McDavid Harrison K, Ling Q, Song R, Hall HI,. County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008; 18: 919-927.
34. Powles T, Bower M, Shamash J, et al. Outcome of patients with HIV-related germ cell tumours: a case-control study. Br J Cancer. 2004; 90: 1526-1530.
35. Powles T, Nelson M, Bower M,. HIV-related testicular cancer. Int J STD AIDS. 2003; 14: 24-27.
36. Fossa SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007; 99: 533-544.
37. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012; 104: 357-370.
38. Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012; 30: 3752-3763.